Several posters will be presented at the upcoming @theaacr.bsky.social AM that feature cohorts created by @su2c.bsky.social funded teams. Check out the following abstracts for more information: 2713, 6473, 1045, 7742, and 5908. Congrats to all the presenters! #AACR26

Massive congratulations to past and present members of the SU2C community selected as @theaacr.bsky.social fellows: Bill Nelson, Christina Curtis, Anil Rustgi, Anthony Letai, Charles Roberts, Alice Shaw, Ross Levine, Kim Stegmaier, Matt Vander Heiden, and Jen Wargo! www.aacr.org/about-the-aa...

In a wide-ranging #SU2CInnovationSummit, scientists from many different fields discussed methods, technologies, and systems for catching cancers at their earliest stages and selecting the best treatments for every patient. #StandUpToCancer

Another #SU2CInnovationSummit was focused on developing novel approaches for detecting and treating brain cancers called gliomas. #StandUpToCancer

In a #SU2CInnovationSummit held today, researchers reviewed the latest data on the surge in early-onset cancers and discussed potential approaches for improving early detection and treatment of cancer in these younger patients. #StandUpToCancer

Researchers at the #SU2CScientificSummit gave us their one-word descriptions of #StandUpToCancer. Each word and phrase is a testament to our mission: Raise awareness and fund research to detect and treat cancers with the aspiration to cure all patients. 💛

We'd like to thank all the #StandUpToCancer researchers, advisors, reviewers, advocates, and funding collaborators who joined us for another motivational and powerful SU2C Scientific Summit. Together, the path to new cures is becoming clearer than ever. 🧡

The annual #SU2CScientificSummit brings together top scientists to drive bold discoveries and transformative change in cancer research.

Exciting times at the 2026 #SU2CScientificSummit @su2c.bsky.social! Delighted to share that I’ve joined my friend Dr. Peter Jones as co-leader of the Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team, which moves promising potential combination therapies for cancer into clinical trials.

Thank you to our wonderful keynote speakers, #StandUpToCancer Prostate Cancer Dream Team leader Dr. Arul Chinnaiyan and SU2C Science Advisory Committee Vice Chair Dr. John Carpten. #SU2CScientificSummit

A full day has begun at the #SU2CScientificSummit! We received inspiring remarks from #StandUpToCancer President and CEO Dr. Julian Adams, SU2C Science Advisory Committee Chair Dr. William G. Nelson, @theaacr.bsky.social CEO Dr. Marge Foti, and SU2C co-founder Sherry Lansing.

The other #SU2CInnovationSummit held today was a collaboration with the Farrah Fawcett Foundation, gathering researchers, advocates, & other stakeholders to chart a path forward for the early detection, screening, and treatment of HPV-related anal and oropharyngeal cancers. #StandUpToCancer

In one #SU2CInnovationSummit held today, leading researchers discussed advances in cancer theranostics. Theranostics are like multitalented homing beacons: Molecules that allow doctors to clearly see tumors with imaging, like a PET scan, and that can also precisely deliver radiation to those tumors.

The #SU2CScientificSummit and five #SU2CInnovationSummits are taking place this week in Pasadena, California! Hundreds of scientists will be discussing the latest in cancer research and treatment, and identifying opportunities for rapid progress. Let the innovation begin! #StandUpToCancer

Gastric cancer claims more than 750,000 lives each year. In partnership with @cancerresearchuk.org, we’ve extended funding for a research dream team that has developed a way to find and stop #gastriccancer at its earliest stages, when treatment is most effective. standuptocancer.org/latest-news/...

Lung cancer screening can save lives. Black men have the highest death rates from #lungcancer. A community-engaged strategy for overcoming screening barriers developed with @SU2C funding may help change that. @medunivsc.bsky.social @vcumassey.bsky.social www.mdpi.com/2072-6694/17...

A new clinical trial funded by @su2c.bsky.social and J&J for people with a difficult-to-treat disease called AL-amyloidosis. The trial, led by Dr. Suzanne Lentzsch of @columbiamed.bsky.social, will test the combination of (1/2) www.sciencedirect.com/science/arti...

Impact-AL: A phase 2 clinical trial of teclistamab and daratumumab in previously untreated AL amyloidosis

Background and Significance: Systemic immunoglobulin light chain (AL) amyloidosis remains a challenging disease, with current frontline regimens faili…

sciencedirect.com

Dr. Julian Adams, President and CEO of @su2c.bsky.social, is at the @milkeninstitute.org today discussing innovations in #EarlyDetection and equitable cancer care. Panelists include @boehmjesse.bsky.social from @break-cancer.bsky.social, Ian Foulkes from @cancerresearchuk.org, and Maddie Musselman

Last week, Dr. Julian Adams, President and CEO of @su2c.bsky.social, spoke at the #LongwoodHealthcareLeaders #BostonCEO 2025. The event covered a wide range of topics, including health equity and patient access to care. It was attended by top leaders in healthcare and select Nobel Laureates.

Will Freed-Pastor from @danafarber.bsky.social gave a phenomenal presentation on cryptic #antigens and their potential as targets for TCR-based therapies at the @theaacr.bsky.social Special Conference in #PancreaticCancer Research.

The 18th @theaacr.bsky.social Conference on the Science of #HealthDisparities took place in Baltimore from September 18-21. A special session held on Saturday featured a panel discussion, grantees, advocates, and other members of the @su2c.bsky.social community. Thanks to all in attendance!

Michael Goggins, Maria Irene Canto, and a team of @su2c.bsky.social and @lustgarten.org funded researchers at @hopkinsmedicine.bsky.social have found a link between dilation of the #pancreatic duct and the development of #pancreaticcancer in high-risk individuals. www.ghadvances.org/article/S277...

The Data for Children's and Young People's Cancer Programme Award is a new partnership between @su2c.bsky.social and @cancerresearchuk.org to support data-driven solutions to common challenges in this space. More information: cruk.ink/4njVxWU Informational webinar: cruk.ink/4gdAcw9

The @su2c.bsky.social Catalyst®-@genentech.bsky.social‬ Team lpublished the results of Arm C of the NeoACTIVATE trial in the European Journal of Cancer showing that neoadjuvant atezolizumab/tiragolumab is a promising treatment regimen in stage III melanoma www.ejcancer.com/article/S095...

NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanoma

Neoadjuvant ± adjuvant immunotherapy improves event-free survival (EFS) versus adjuvant immunotherapy alone for high-risk resectable Stage III melanoma. However, the optimal regimen balancing efficacy...

ejcancer.com

A study in NatureComms uses #ML and a clinicogenomic dataset generated by the @su2c.bsky.social -@ ‪@acscan.bsky.social‬ Lung Cancer Dream Team to improve immune checkpoint monotherapy or combination #immunotherapy-#chemotherapy for patients with #NSCLC. www.nature.com/articles/s41...

Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC - Nature Communications

The approval of first line immune checkpoint blockade (ICB) has improved outcomes for patients with metastatic non-small cell lung cancer (mNSCLC), however, whether patients would benefit more from IC...

nature.com

Request for Applications! The @su2c.bsky.social - @CRUK Prevention, Early Stage Detection, and Interception of Recurrence Challenge is now open! For more information, click the link below or search Stand Up To Cancer in Proposal Central under Grant Opportunities. standuptocancer.org/science/gran...

According to a paper published in ‪@cp-cancercell.bsky.social‬ by the @su2c.bsky.social‬ Colorectal Cancer Dream, they have been able to use mutagenic agents to engineer an MMRd genotype in immunoresistant cells to generate an immunogenic phenotype www.cell.com/cancer-cell/...

Induction of a mismatch repair deficient genotype by tailored chemical mutagenesis in experimental models of cancer

Rousseau et al. show that tailored mutagenic chemical treatment induces a mismatch repair deficient genotype by epigenetic Msh2 silencing leading to potent immune response in immunoresistant tumor mod...

cell.com

The GBM chatbot is going live on the @su2c.bsky.social website on 7/16. This AI companion was developed by Jason Binder after his wife was diagnosed with glioblastoma to help patients and family members to understand glioblastoma, explore options, and feel less alone on this journey. #GBMDay

@su2c.bsky.social Convergence 3.1416 Research Team member Raul Rabadan published a review in @CR_AACR examining examples of noncoding mutations in cancer and comparing key AI models developed over the last decade for uncovering cancer-associated noncoding mutations. aacrjournals.org/cancerres/ar...

A project initiated by the @su2c.bsky.social Breast Cancer Dream Team was published in npj precision oncology utilizing cohort-level and individual networks to predict best response in patients with metastatic triple negative breast cancer www.nature.com/articles/s41...